The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells
1999
GF120918 Reverses Drug Resistance in Sarcoma Cells
publication
Evidence: high
Author Information
Author(s): Traunecker H C L, Stevens M C G, Kerr D J, Ferry D R
Primary Institution: CRC Institute for Cancer Studies, University of Birmingham
Hypothesis
Can GF120918 effectively reverse P-glycoprotein-mediated drug resistance in human sarcoma cells?
Conclusion
GF120918 completely reverses drug resistance in MES-Dx5 cells for multiple cytotoxic drugs.
Supporting Evidence
- GF120918 reversed resistance to etoposide, doxorubicin, vinblastine, taxotere, and taxol in MES-Dx5 cells.
- The EC50s for GF120918 to reverse resistance were determined for various drugs.
- The study showed that MES-Dx5 cells had a significant accumulation deficit for certain drugs compared to parental cells.
Takeaway
This study found that a new drug called GF120918 can help cancer cells that are resistant to treatment become sensitive again.
Methodology
The study involved testing the effects of GF120918 on drug resistance in the MES-Dx5 sarcoma cell line.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website